About Ixazomib or Ninlaro
Ixazomib is a proteasome inhibitor including a combination of lenalidomide and dexamethasone that is prescribed for multiple myeloma patients who have received at least one previous therapy.
Strength: Ninlaro is available in various strengths including 2.3 mg of Ixazomib equivalent to 3.3 mg of Ixazomib citrate, 3 mg of Ixazomib equivalent to 4.3 mg of Ixazomib citrate, and 4 mg of Ixazomib equivalent to 5.7 mg of Ixazomib citrate.
Recommended Dosage
The initial recommended dosage is 4 mg orally in a week on Days 1, 8, and 15 following the 28-day cycle. The dosage must be revised and reduced to 3 mg or below in cases of reduced kidney and liver function.
Important: In case of any severe effects from the medication, please consult your treating doctor.
Warning & Precautions
Common side effects of Ixazomib
Use in Specific Population
It is necessary to reduce the dosage of Ixazomib in cases of moderate to severe hepatic impairment. Reduce the dose to 3 mg in individuals with severe renal impairment or end-stage renal disease who require dialysis.
For the medicine procurement, we follow a simple four-step process.
When importing medication, we will need the following documents from the patient:
Once we have all these documents, the Sansfro team will initiate the application process for an import license. This license is essential to ensure that we can obtain the necessary medication once it receives government approval.
No news found.
Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.
Know More...How does NINLARO work?
NINLARO is a proteasome inhibitor that acts by inhibiting enzymes within cells, slowing cancer cell proliferation.
How is NINLARO taken?
NINLARO is taken orally as a capsule once a week, according to your doctor’s recommendation, or on Days 1, 8, and 15 following the 28-day cycle. The dosage must be revised by the doctor and reduced to 3 mg or below in cases of reduced kidney and liver function.
What are the potential side effects of NINLARO?
Nausea, diarrhea, exhaustion, vomiting, low blood platelet levels, and peripheral neuropathy (numbness or tingling in the hands and feet) are common adverse effects of NINLARO or Ixazomib.
Please note that Ixazomib is the Active Pharmaceutical Ingredient of the product Ninlaro.
How should I manage the side effects of NINLARO?
It is critical to discuss any adverse effects you have with your doctor. They can advise you on how to manage side effects and, if required, change your treatment plan.
Can I take NINLARO while pregnant or breastfeeding?
Since NINLARO has the potential to harm an unborn baby, it is typically not recommended during pregnancy. It is also recommended that you should not breastfeed while using NINLARO.
What is the price of NINLARO in India?
NINLARO price in India depends on the product requirement and the country where the product is ordered. Request more details by reaching out to our Patient Support Team at (+91) 9315705373 or help@sansfro.com
Medical counselor
India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.